RxDoctor Payments Data

Candace Buckley, DPM

Podiatrist · Pomona, CANPI 1558795757

Payments from drug & device makers

$1,686in general payments, 2019–2025

Across 58 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$498
  • Integra Lifesciences Corporation$229
  • Melinta Therapeutics, LLC$224
  • Sportstek Medical, Inc$170
  • Smith+Nephew$157
  • Sandoz$118
  • plus $289 from 13 others

What the payments were for

  • Travel & lodging$1408%
  • Food & beverage$1,09065%
  • Education$45627%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Arthrex2$498
Integra Lifesciences Corporation7$229
Melinta Therapeutics, LLC13$224
Sportstek Medical, Inc2$170
Smith+Nephew13$157
Sandoz6$118
Medline Industries LP1$45
DJO, LLC2$29
Organogenesis Inc.1$28
Zimmer Biomet1$25
Merck2$24
Rikco International, LLC1$23
Osiris Therapeutics Inc.1$21
Tactile Systems Technology Inc1$20
Misonix Inc1$16
Zyla Life Sciences, Inc.1$15
Polarityte, Inc.1$15
Paragon 28, Inc.1$15
Stryker1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,686 in reported general payments places this provider in the 60th percentile of 721 podiatrist providers in California.

See all podiatrist providers in California

Medicare billing

Part B allowed, 2024
$1,622
Medicare patients
14
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.16$5,467
Terbinafine Hcl98$885
Ciclopirox38$657
Mupirocin39$537
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$286
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc14$211
Gabapentin11$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$157$5,46716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 721 podiatrist providers in California.

Other podiatrist in Pomona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →